A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

    November 2025 in “ Journal of Clinical Medicine ”
    Sara Lambiase, Danilo Cavalloro, Arnaldo Cioni … Laura Diluvio
    Studysummary The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    2. Effect of Baricitinib in Patients with Alopecia Areata: Usefulness of Trichoscopic Evaluation Journal of the European Academy of Dermatology and Venereology · 2023
    3. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    4. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature Journal of cutaneous medicine and surgery · 2019
    5. Quality of Life in Alopecia Areata: A Sample of Tunisian Patients Dermatology Research and Practice · 2013
    6. Topical and Intralesional Therapies for Alopecia Areata Dermatologic therapy · 2011